BofA/Merrill Lynch Downgrades Pacira Pharmaceuticals (PCRX) to Neutral
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $25.54 --0%
Rating Summary:
11 Buy, 16 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 1
Rating Summary:
11 Buy, 16 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 1
Join SI Premium – FREE
BofA/Merrill Lynch downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $91.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Papa John\'s (PZZA) to Underperform, 'Management turnover increases NT uncertainty'
- Krystal Biotech (KRYS) PT Raised to $396 at BofA Securities
- Realty Income expands credit and commercial paper to $5.5B each
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
